tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Morning Movers: MeridianLink jumps after pact to be acquired by Centerbridge
PremiumThe FlyMorning Movers: MeridianLink jumps after pact to be acquired by Centerbridge
27d ago
4D Molecular reports 2Q EPS (98c) vs (63c) last year
Premium
The Fly
4D Molecular reports 2Q EPS (98c) vs (63c) last year
27d ago
Promising Phase 2 Trial Results and Strategic Developments Support Buy Rating for 4D Molecular Therapeutics
Premium
Ratings
Promising Phase 2 Trial Results and Strategic Developments Support Buy Rating for 4D Molecular Therapeutics
1M ago
4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration?
PremiumCompany Announcements4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration?
2M ago
Optimistic Buy Rating for 4D Molecular Therapeutics Amid Strategic Advancements and Market Interest
Premium
Ratings
Optimistic Buy Rating for 4D Molecular Therapeutics Amid Strategic Advancements and Market Interest
2M ago
Closing Bell Movers: Datadog jumps 11% on S&P 500 inclusion
Premium
The Fly
Closing Bell Movers: Datadog jumps 11% on S&P 500 inclusion
2M ago
Promising Advancements in 4D Molecular Therapeutics’ Gene Therapy Programs Drive Buy Rating
PremiumRatingsPromising Advancements in 4D Molecular Therapeutics’ Gene Therapy Programs Drive Buy Rating
4M ago
4D Molecular price target lowered to $38 from $45 at Barclays
Premium
The Fly
4D Molecular price target lowered to $38 from $45 at Barclays
4M ago
4D Molecular Therapeutics Reports Increased Quarterly Loss
Premium
Company Announcements
4D Molecular Therapeutics Reports Increased Quarterly Loss
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100